MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Homology Medicines Revenue 2011-2026 | FIXX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Homology Medicines
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.7 M | - | 3.21 M | 34 M | 2.7 M | 1.67 M | 3.68 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.7 M | 1.67 M | 16.5 M |
Quarterly Revenue Homology Medicines
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 1.86 M | 3.2 M | 802 K | - | 802 K | 802 K | 802 K | - | 1.68 M | 2.19 M | 29.3 M | - | 567 K | 567 K | 588 K | - | 441 K | 392 K | 270 K | - | 5.32 M | 5.32 M | 823 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 29.3 M | 270 K | 3.1 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.52 | -0.85 % | $ 1.05 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
AC Immune SA
ACIU
|
27.3 M | $ 3.09 | -6.93 % | $ 229 M |  Schweiz |
 |
Adagene
ADAG
|
10.2 M | $ 3.94 | 0.77 % | $ 222 M |  China |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
2.34 M | $ 4.01 | -2.2 % | $ 105 M | Schweiz |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 227.41 | -0.29 % | $ 5 B |  Danmark |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.78 | -0.41 % | $ 4.25 M | China |
 |
argenx SE
ARGX
|
36.4 M | $ 684.77 | -3.01 % | $ 25 B |  Niderland |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.5 | 4.78 % | $ 8.42 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.45 | -3.97 % | $ 370 M | Britain |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
167 M | $ 14.11 | -2.76 % | $ 207 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioCardia
BCDA
|
477 K | $ 1.23 | -3.91 % | $ 26.1 M | USA |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioNTech SE
BNTX
|
482 M | $ 90.0 | -5.12 % | $ 27.2 B | Germany |
 |
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | USA |
 |
Cara Therapeutics
CARA
|
21 M | - | -3.03 % | $ 260 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.44 | 0.29 % | $ 7.49 B |  Israel |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 6.55 | 2.5 % | $ 179 M | Israel |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 10.35 | -6.76 % | $ 925 M | USA |
 |
Burford Capital Limited
BUR
|
330 M | $ 8.22 | -0.72 % | $ 1.36 B | Britain |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | USA |